MYC: Master Regulator of Immune Privilege

Trends in Immunology

Volumn 38, Issue 4, 2017, Pages 298-305

  Casey, Stephanie C ^a   Baylot, Virginie ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; MYC PROTEIN; MYC PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADAPTIVE IMMUNITY; CARCINOGENESIS; GENE INACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NONHUMAN; ONCOGENE MYC; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD274; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR ESCAPE; TUMOR SUPPRESSOR PROTEINS;

EID: 85013459391     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.01.002     Document Type: Review

References (74)

1. 1 Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
2. 2 Dang, C.V., MYC on the path to cancer. Cell 149 (2012), 22–35.
3. 3 Lin, C.Y., et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151 (2012), 56–67.
4. 4 Nie, Z., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151 (2012), 68–79.
5. 5 Walz, S., et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511 (2014), 483–487.
6. 6 Felsher, D.W., Bishop, J.M., Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4 (1999), 199–207.
7. 7 Jain, M., et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 (2002), 102–104.
8. 8 Shachaf, C.M., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004), 1112–1117.
9. 9 Weinstein, I.B., Joe, A., Oncogene addiction. Cancer Res. 68 (2008), 3077–3080.
10. 10 Wu, C.H., et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 13028–13033.
11. 11 Evan, G., et al. Integrated control of cell proliferation and cell death by the c-Myc oncogene. Philos. Trans. R. Soc. Lond. B Bio. Sci. 345 (1994), 269–275.
12. 12 Eisenman, R.N., Deconstructing Myc. Genes Dev. 15 (2001), 2023–2030.
13. 13 Felsher, D.W., Bishop, J.M., Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 3940–3944.
14. 14 Marinkovic, D., et al. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int. J. Cancer 110 (2004), 336–342.
15. 15 Pelengaris, S., et al. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3 (1999), 565–577.
16. 16 Chin, L., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999), 468–472.
17. 17 Fisher, G.H., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15 (2001), 3249–3262.
18. 18 Huettner, C.S., et al. Reversibility of acute B-cell leukaemia induced by BCR–ABL1. Nat. Genet. 24 (2000), 57–60.
19. 19 Xie, W., et al. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene 18 (1999), 3593–3607.
20. 20 Moody, S.E., et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2 (2002), 451–461.
21. 21 Wang, R., et al. Activation of the met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153 (2001), 1023–1034.
22. 22 Ewald, D., et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273 (1996), 1384–1386.
23. 23 Gunther, E.J., et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17 (2003), 488–501.
24. 24 Felsher, D.W., Reversibility of oncogene-induced cancer. Curr. Opin. Genet. Dev. 14 (2004), 37–42.
25. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18 (2010), 485–498.
26. 26 Soucek, L., et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13 (2007), 1211–1218.
27. 27 Majeti, R., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138 (2009), 286–299.
28. 28 Casey, S.C., et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352 (2016), 227–231.
29. 29 Mittal, D., et al. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
30. 30 Pardoll, D., Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42 (2015), 523–538.
31. 31 Yaguchi, T., Kawakami, Y., Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol. 28 (2016), 393–399.
32. 32 Dong, H., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5 (1999), 1365–1369.
33. 33 Freeman, G.J., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000), 1027–1034.
34. 34 Li, Y., et al. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk. Lymphoma 53 (2012), 2015–2023.
35. 35 Parsa, A.T., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13 (2007), 84–88.
36. 36 Akbay, E.A., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3 (2013), 1355–1363.
37. 37 Atefi, M., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 20 (2014), 3446–3457.
38. + T lymphocytes. Am. J. Pathol. 183 (2013), 1971–1980.
39. 39 Spranger, S., et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
40. 40 Dorand, R.D., et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353 (2016), 399–403.
41. 41 Lastwika, K.J., et al. Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non-small cell lung cancer. Cancer Res. 76 (2016), 227–238.
42. 42 Dong, Y., et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 33 (2014), 4632–4642.
43. 43 Cha, Y.J., et al. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 97 (2016), 73–80.
44. 44 Kan, G., Dong, W., The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 3063–3071.
45. 45 Skoulidis, F., et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5 (2015), 860–877.
46. 46 Restifo, N.P., Can antitumor immunity help to explain ‘oncogene addiction’?. Cancer Cell 18 (2010), 403–405.
47. 47 Felsher, D.W., MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 1 (2010), 597–604.
48. 48 Delmore, J.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146 (2011), 904–917.
49. 49 Mertz, J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16669–16674.
50. 50 Yao, W., et al. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Oncotarget 6 (2015), 34669–34679.
51. 51 Filippakopoulos, P., Selective inhibition of BET bromodomains. Nature 468 (2010), 1067–1073.
52. 52 Zhu, H., et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16 (2016), 2829–2837.
53. 53 Wilmott, J.S., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18 (2012), 1386–1394.
54. 54 Sweis, R.F., et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4 (2016), 563–568.
55. 55 Taylor, C., et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13 (2007), 5133–5143.
56. 56 Steinberg, S.M., et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol. Res. 2 (2014), 1044–1050.
57. 57 Khalili, J.S., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18 (2012), 5329–5340.
58. 58 Otsuka, A., et al. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin. Cancer Res. 21 (2015), 1289–1297.
59. 59 Holtzhausen, A., et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol. Res. 3 (2015), 1082–1095.
60. 60 Kumai, T., et al. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br. J. Cancer 109 (2013), 2155–2166.
61. 61 Kudo-Saito, C., et al. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15 (2009), 195–206.
62. 62 Green, D.R., et al. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9 (2009), 353–363.
63. 63 Schlee, M., et al. c-Myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int. J. Cancer 120 (2007), 1387–1395.
64. 64 Stark, G.R., et al. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998), 227–264.
65. 65 Dunn, G.P., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002), 991–998.
66. 66 Schreiber, R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
67. 67 Marcus, A., et al. Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol. 122 (2014), 91–128.
68. 68 Champsaur, M., Lanier, L.L., Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235 (2010), 267–285.
69. 69 Pfeifer-Ohlsson, S., Spatial and temporal pattern of cellular myc oncogene expression in developing human placenta: Implications for embryonic cell proliferation. Cell 38 (1984), 585–596.
70. 70 Rydnert, J., et al. Temporal and spatial pattern of cellular myc oncogene expression during human placental development. Placenta 8 (1987), 339–345.
71. 71 Petroff, M.G., et al. B7 family molecules are favorably positioned at the human maternal–fetal interface. Biol. Reprod. 68 (2003), 1496–1504.
72. 72 Scognamiglio, R., et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164 (2016), 668–680.
73. 73 Casey, S.C., et al. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol. Res. 58 (2014), 282–291.
74. 74 Casey, S.C., et al. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J. Immunother. Cancer, 2, 2014, 24.